Gilgamesh in the news! bbc.com/news/business-…

this is perfect!

⛳️Pre-print drop: Into Psychedelic Therapy: Beyond Brain, Embracing Culture! 🌀 We explore how soculturally situated embodiment plays a crucial role in the development and treatment of mental health conditions & how psychedelic experience acts as self-narrative pattern shift 🎨

Pat Condell on war crimes, nauseating hypocrisy, freedom, and the self-pitying burden on humanity of Arab political culture. Hypocrisy Over Gaza youtu.be/_Ugsv5u-sW0?si… via YouTube

Almost every talk at this year's (lovely) MGH psychedelic conference noted a need to better understand the psychotherapy paired with psychedelics. So, it seemed like a good time to share our preprint: “Psychedelic-assisted psychotherapy: Where is the psychotherapy research?”

Yashar Ali 🐘 Can we get #TikTokisAPsyOp trending for the love of god

America’s top universities should abandon their long misadventure into politics, retrain their gaze on their core strengths and rebuild their reputations as centers of research and learning. My take:

Gilgamesh's first paper! GM-1020: a novel, orally bioavailable NMDA receptor antagonist with rapid and robust antidepressant-like effects at well-tolerated doses in rodents rdcu.be/dvaHx

Excited to announce Gilgamesh's 1st peer-reviewed publication for GM-1020, our best in class oral ketamine analog. It is designed to have reduced dissociative/sedative properties which can potentially make it suitable for at-home use. nature.com/articles/s4138…

Nature Personalized medicine: Time for one-person trials nature.com/articles/52060…

"The Harvard motto is Veritas—truth. But the truth is that the message that members of the Harvard community receive every day—in emails, trainings, posters, pamphlets, and meetings—concerns DEI. The message is that what matters most, certainly above the search for truth, is how

Temperature inversion at Stowe,VT this weekend. Everested (>8848 meters descent) the mountain both days with my son. Might need Monday for recovery 😅

Gilgamesh Announces Initiation of Phase 2a Trial of GM-1020 (a novel oral NMDA receptor antagonist) in Major Depressive Disorder prnewswire.com/news-releases/…

Extremely proud of our team!

Breaking: AbbVie Inks Deal with Gilgamesh Pharmaceuticals AbbVie has become the latest large pharmaceutical company to dip its toes into psychedelic drug development as it announced what might be the most substantial foray of its kind this morning. psychedelicalpha.com/news/breaking-…

Yeah, no surprise that hippocampal recordings of overtrained rats on linear track show low-dimensional manifold. The fantasy does not scale to the whole brain - what a surprise 😀

.Scott Galloway offers a powerful essay on why it is so urgent that social media companies develop age-gating, and why it is such a scandal that they won't even try. It will happen, though perhaps not in the USA first. profgalloway.com/age-gating/

Excited to share our new preprint! 1/5 In humans and mice, we studied the impacts of psychedelics in the days/weeks after a trip. What we found amounts to a sort of stop-&-smell-the-roses effect. A neural basis for the afterglow. biorxiv.org/content/10.110…

After a high dose of psilocybin, the brain desynchronizes at a massive scale, causing loss of our sense of self, time, and space. This may drive the burst of plasticity caused by psychedelics. The next day, brain activity has largely returned to normal, but an echo remains – a

The FDA decision on Lykos' MDMA application is bittersweet at best, especially for those who do need treatment for treatment resistant PTSD. The decision is also entirely justified and I believe the right one. Rick Doblin and MAPS openly treated the FDA process with so much